Dynamic of humoral response to SARS-CoV-2 anti-Nucleocapsid and Spike proteins after CoronaVac vaccination

Diagn Microbiol Infect Dis. 2022 Mar;102(3):115597. doi: 10.1016/j.diagmicrobio.2021.115597. Epub 2021 Nov 19.

Abstract

This study aimed to calculate the seroconversion rate and IgG antibody dynamic range of the CoronaVac vaccine in healthcare workers (HCWs) after immunization. Serum samples from 133 HCWs from Southern Brazil were collected 1 day before (Day 0) and +10, +20, +40, + 60, +110 days after administering the vaccine's first dose. Immunoglobulin G (IgG) was quantified using immunoassays for anti-N-protein (nucleocapsid) antibodies (Abbott, Sligo, Ireland) and for anti-S1 (spike) protein antibodies (Euroimmun, Lübeck, Germany). Seroconversion by day 40 occurred in 129 (97%) HCWs for the S1 protein, and in 69 (51.87%) HCWs for the N protein. An absence of IgG antibodies (by both methodologies), occurred in 2 (1.5%) HCWs undergoing semiannual rituximab administration, and also in another 2 (1.5%) HCWs with no apparent reason. This study showed that CoronaVac has a high seroconversion rate when evaluated in an HCW population.

Keywords: CoronaVac; Immunization; Immunoglobulin G; Pandemic; Public health; Vaccine.

MeSH terms

  • Antibodies, Viral
  • COVID-19*
  • Humans
  • Nucleocapsid
  • SARS-CoV-2*
  • Spike Glycoprotein, Coronavirus
  • Vaccination

Substances

  • Antibodies, Viral
  • Spike Glycoprotein, Coronavirus